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The interaction between heparin, a polyanion, and a polycationic dendrimer with a glycine core and
lysine branches Gly–Lys63(NH2)64 has been investigated. Complexation was assessed by transmission
electron microscopy, size and zeta potential measurements, methylene blue spectroscopy, and
measuring the anti-coagulant activity of heparin in vitro and in vivo. Complete association between
the heparin and the dendrimer occurred a 1:1 mass ratio (2:1 molar ratio or þ/charge ratio) with
formation of quasi-spherical complexes in the size range of 99–147 nm with a negative zeta potential
(47 mV). Heparin–dendrimer (dendriplex) formation led to a concentration-dependent neutralization
of the anticoagulant activity of heparin in human plasma in vitro, with complete loss of activity at a 1:1
mass ratio. The anticoagulant activity of the dendriplexes in Sprague-Dawley rats was also evaluated
after subcutaneous administration with uncomplexed heparin as a comparator. The in vivo antic-
oagulant activity of heparin in plasma, evaluated using an antifactor Xa assay, was abolished after
complexation. Measurement of [3H]-heparin showed that both free heparin and dendriplexes were
present in plasma and in organs. Such data conﬁrmed stably the formation of dendriplexes, which could
be essential in developing novel dendrimer-based anti-angiogenic therapeutics suitable in combinatory
therapeutics and theranostics.
& 2011 Elsevier B.V. All rights reserved.1. Introduction
Dendrimers are three-dimensional nanocontainers synthesized
in a stepwise manner by attaching branching units to an emanating
core [1]. Their size, molecular weight and surface functionalities can
be easily controlled [1]. We have reported recently and for the ﬁrst
time the intrinsic anti-angiogenic activity of cationic 6th generation
poly-L-lysine (PLL) dendrimer (MW 8149 Da) using a panel of
in vitro and in vivo assays [2]. Systemic administration of only two
doses injected intravenously at 50 mg/kg PLL-dendrimer resulted in
persistent accumulation in solid tumor sites, with reduced vascular-
ization, extensive apoptosis/necrosis within the tumor tissue and
statistically signiﬁcant but moderate reduction in tumor volume, inll rights reserved.
Institute of Pharmaceutical
ilding, 150 Stamford Street,
5.
. Al-Jamal),the absence of any remarkable histological or physiological abnorm-
ality. The mechanism of PLL-dendrimer’s anti-angiogenic activity is
not yet fully understood however previous studies have identiﬁed
heparin as a potential target for anti-angiogenesis therapy by
binding to protamine, an arginine-rich basic protein of 4300 Da,
that leads to inhibition of angiogenic growth factor activity [3].
Heparin is a polydisperse negatively charged polysaccharide
(6000–30,000 Da). The relatively high content of sulfate groups
(anionic groups) in heparin is mainly responsible for the antic-
oagulant and pro-angiogenic characteristics of the compound [4,5].
It has also been recognized that heparin potentiates the activity of
angiogenic growth factors although this mechanism is not yet clearly
understood [6]. Moreover, Azizkhan and coworkers reported that
heparin released by mast cells accumulates at the tumor site,
enhancing the migration of capillary endothelial cells prior to
ingrowth of new blood capillaries [7]. Heparin, when present in the
mammalian circulatory system, functions physiologically as an
anticoagulant.
The present study is based on the hypothesis that 6th genera-
tion cationic poly-L-lysine-dendrimers Gly–Lys63(NH2)64 [2,8]
K.T. Al-Jamal et al. / Results in Pharma Sciences 2 (2012) 9–1510previously reported to accumulate at the tumor site and exhibit
an intrinsic therapeutic anti-angiogenic activity that has the
capability to bind electrostatically to the negatively charged
heparin and thus exhibit heparin neutralizing activity. We tested
the hypothesis by assessing the interaction between PLL-dendri-
mer and heparin using Methylene blue binding assay, dynamic
light scattering and assessing heparin anti-coagulant activity by
anti-factor Xa assay. Complexation of heparin and PLL-dendrimer
was achieved and could lead to deactivation of heparin antic-
oagulant activity in vitro and after subcutaneous administration
in vivo.2. Materials and methods
2.1. Materials
Unfractionated heparin sodium salt grade I-A from porcine
intestinal mucosa (187 USP units/mg) (MW 6000–30,000 Da),
hydrogen peroxide, isoamyl alcohol, methylene blue (Sigma, USA),
AccucolorTM heparin and AccuclotTM reference plasma (Sigma
Diagnostics, USA), [3H]-heparin (sodium salt) (speciﬁc radioactivity
0.32 mCi/mg) (Perkin Elmer, USA), Sagatals (Rhone Merieux, UK),
BD EclipseTM needles, 2.7 ml BD vacutainerTM tubes (Beckton
Dickinson, USA), Biosols tissue solubilizer and self-acidiﬁed Bioscints
scintillation cocktail (National Diagnostics, UK).2.2. Synthesis of Gly–Lys63(NH2)64 dendrimer
The synthesis of the water soluble, glycine cored, polylysine
dendrimer bearing 64 surface amino groups and employed in this
study (MW 8149 Da) has been described in detail [8].2.3. Preparation of heparin dendriplexes
The dendriplexes were formed spontaneously by mixing equal
volumes (1 ml) of heparin (1 mg/ml) and the dendrimer (0.5, 1, 2,
3, 4 and 5 mg/ml) in aqueous solution, followed by gentle shaking
of the colloidal dispersions on a platform shaker at 30 rpm for 1 h.2.4. Transmission electron microscopy, size and zeta potential
measurement of the dendriplexes
Heparin dendriplexes were examined by transmission electron
microscopy (TEM). A drop of the suspension was placed on a grid
with a support ﬁlm of Formvar/carbon previously glow dis-
charged (Emitech). Excess material was blotted off with a ﬁlter
paper and the dendriplexes negatively stained with 1% uranyl
acetate, prior to viewing on a Philips CM 120 Bio Twin transmis-
sion electron microscope (Einhoven, Netherlands) using a lab
6 emitter and 120 KV. Images were captured on Kodak SO-163
negative ﬁlm and printed on Ilford multi-grade paper.
For size measurements, the mixtures were diluted 5 times in
deionised water and sized by photon correlation spectroscopy
(PCS) using a PCS 4700 Malvern submicron particle analyzer
(Malvern Instruments, Malvern, UK, He–Ne laser, 901 angle of
measurement). Measurements were repeated for 7 consecutive
days and again at 14 days, to check for aggregation. The zeta
potentials of the systems were measured using a Zetasizer 3000
(Malvern Instruments, Malvern, UK) using dispersions (2 ml)
diluted 5, 10 or 20 times, depending on the original dendrimer
concentration. The average of 3 measurements was used and
results expressed as a Z-average (nm)7S.D. and zeta potential
(mV)7S.D.2.5. Methylene blue spectroscopy
A solution containing heparin–methylene blue (MB) complex
was titrated with the dendrimer. A heparin–MB complex was
prepared by mixing MB solution (1 ml, 20 mM), heparin solution
(0.5 ml, 2.7 mM) and the calculated volume of dendrimer solution
(122.7 mM) to achieve a total volume of 2 ml. MB, heparin and
dendrimer ﬁnal concentrations were 10, 0.725 and 0.16–10 mM,
respectively. Absorption spectra for MB–heparin, before and after
titration with the dendrimer, were obtained between 400 and
800 nm at a scan rate of 1200 nm/min using a plastic cuvette in a
Beckman DUs 650 Spectrophotometer (USA). A664/A568 ratio was
used to calculate the ratio at maximum association. The experi-
ments were repeated in quadruplicate.2.6. Estimation of the anticoagulant activity of dendriplexes in vitro
The anticoagulant activity of heparin and the heparin dendri-
plexes in vitro was tested by antifactor Xa assay, using an
AccucolorTM heparin kit (micro-plate method). AccucolorTM
heparin is intended for the quantitative determination of ther-
apeutic heparin in human plasma. Lyophilized human antithrom-
bin III (AT-III), bovine factor Xa, and factor Xa substrate were
reconstituted in deionized water as directed by the manufacturer.
Lyophilized AccuclotTM reference plasma was reconstituted in
deionized water immediately before use.
A solution of heparin in saline was prepared as a stock solution
(8 USP unit/ml or 44 mg/ml) and a calibration curve of heparin
(0.1–0.8 IU/ml) obtained by serial dilution of the stock in standard
human plasma. Heparin dendriplexes were prepared in standard
human plasma, at dendrimer/heparin (0.1–0.8 IU/ml) mass ratios
of 0.1, 0.5, 1, 2, 3, 4 and 5:1. An additional 1:2 dilution of all
standards and dendriplexes was made by diluting 100 ml of the
plasma standard with 100 ml saline before running the assay. To
run the assay, AT-III (75 ml) was dispensed to individual wells of a
96-well microstate plate and incubated with the diluted standard
(25 ml) and factor Xa (75 ml), with factor Xa substrate (75 ml)
subsequently added and incubated at 37 1C for 2, 1 and 10 min
after each addition, respectively. The reaction was stopped with
20% acetic acid (75 ml). A405 was blanked using these reagents in
the following order; acetic acid, AT-III, plasma, factor Xa and the
substrate, and then measured using a Dynex MRX Microplate
Reader 133 (Dynex, UK). When A405 was plotted against heparin
concentration (units/ml), the anticoagulant activity was inversely
proportional to A405. Measurements were carried out in triplicate.2.7. Estimation of the anticoagulant activity of dendriplexes in vivo
in the rat
2.7.1. Animals
Female, Sprague-Dawley rats (176.4 g710.5 g) (B and K Uni-
versal Ltd., UK) were caged in groups of 3–8 with free access to
water. A temperature of 19–22 1C was maintained, with a relative
humidity of 45–65%, and a 12 h light/dark cycle. Animals were
acclimatized for 7 days before each experiment and were fasted
for 12 h before dosing. All procedures followed the 1989 UK
Home Ofﬁce ‘‘Code of Practice for the Housing and Care of
Animals used in Scientiﬁc Procedures’’.2.7.2. Dosing of animals
A subcutaneous heparin dose was used as recommended by
Borchard et al. [9]. The oral heparin dose was determined from
dose-response studies conducted by Leone-Bay et al. [10]. Dose
volumes were chosen as recommended by Diehl et al. [11].
K.T. Al-Jamal et al. / Results in Pharma Sciences 2 (2012) 9–15 11Subcutaneous heparin administration: 20 rats were randomized
into 5 groups of 4 animals each and injected subcutaneously with
a single dose of [3H]-heparin (10 mg/Kg, 1 mCi, 0.2 ml) in the
dorsal neck region. Groups were sacriﬁced at 0 (control), 1, 3,
6 and 24 h after administration.
Subcutaneous dendriplexes administration: 20 rats were rando-
mized into 5 groups of 4 animals each and injected subcuta-
neously in the dorsal neck region with a single dose of [3H]-
heparin complexed with dendrimer (10 mg/Kg heparin and
30 mg/Kg dendrimer, 1 mCi, 0.2 ml). Groups were sacriﬁced at 0
(control), 1, 3, 6 and 24 h after administration.
Oral heparin administration: 20 rats were randomized into
5 groups of 4 animals each and gavaged with a single dose of
[3H]-heparin (100 mg/Kg, 1 mCi, 2 ml). Groups were sacriﬁced at 0
(control), 1, 3, 6 and 24 h after administration.2.7.3. Blood collection and radioactivity in plasma and organs
At the scheduled time points (0, 1, 3, 6 and 24 h) post dosing,
animals were anesthetised by intraperitoneal (ip) injection of
pentobarbitone sodium B.P. (72 mg/rat) (Sagatals, 60 mg/ml).
Blood was withdrawn from the abdominal aorta using BD
EclipseTM needles and collected into 2.7 ml BD VacutainerTM
tubes containing 0.129 M sodium citrate (3.8%, 9:1 blood:sodium
citrate ratio) as anticoagulant. The tubes were transferred onto
ice, centrifuged (2500 g, 10 min) at room temperature, and the
plasma immediately harvested and stored at 20 1C. After
sacriﬁce, the heart, lungs, liver, spleen, kidneys, stomach, small
intestine and large intestine were removed and homogenized in
deionised water for 3 min, intermittently, using a tissue homo-
genizer (Model PT-10, Polytron, Switzerland). All samples were
solubilised before radioactivity counting; an aliquot of 0.6 ml of
plasma or 200 mg of each tissue homogenate was solubilised with
1.0 ml of Biosols (National Diagnostics, UK) tissue solubiliser,
shaken overnight at 55 1C, combined with 17 ml of the self-
acidiﬁed Bioscints scintillation cocktail (to eliminate chemilumi-
nescence), and kept in a dark cold room at 4 1C for 72 h beforePolylysine dendrimer 
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Fig. 1. Heparin dendriplexes are spontaneously formed as a result of electrostatic int
illustrated. The number of charges assigned per heparin or dendrimer molecule in the
charge per molecule.counting in a LS6500 Multi-Purpose Scintillation Counter (Beckman,
USA). Colored samples were decolorized with 200–400 ml of 30%
hydrogen peroxide, and with 200–400 ml of isoamyl alcohol added
to stop foaming. Rat plasma volume was calculated to be in the
range of 6.1–7.6 ml based on the formula of 36–45 ml plasma per Kg
of rat body weight [12]. Results were expressed as the percent of the
injected dose per organ, or the percent of the injected dose per g
tissue7S.D. (n¼4). Plasma volume rather than plasma weight was
used in all calculations.
2.7.4. Antifactor Xa assay
The standard curve of free heparin (IU/ml) was established
using the procedure described above in the in vitro study, except
that rat plasma was substituted for human plasma, and 50 ml
of undiluted rat plasma was used instead of 25 ml of diluted
human plasma. A standard curve was prepared by spiking heparin
(0.1–1.6 IU/ml) into control pooled platelet-free rat plasma. Test
plasma samples were assayed within 2 h of collection, or stored at
20 1C and thawed once at 37 1C, 30 min before use.3. Results and discussions
3.1. Shape, size and zeta potential measurement of the dendriplexes
Heparin is a polydisperse polyanionic copolymer composed of
alternating D-glucuronic acid, which is frequently O-sulfated at
C2, and D-glucosamine-N-sulfate with an additional sulfate group
on C6 linked via a-1,4 glycosidic linkage; molecular weights
range from 6000 to 30,000 Da. The heparin used in this experi-
ment had a mean number molecular weight within the range of
17,000–19,000 Da, as speciﬁed by the manufacturer (Sigma, UK).
Gelman and Blackwell [13] reported heparin to have 2.33 sulfate
groups per disaccharide and showed a maximum interaction
between the linear poly(lys) and the heparin at a 2.3:1 amino
acid:disaccharide ratio; the complex adopted an a-helical
conformation.raction 
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eractions by mixing heparin and the cationic dendrimer in aqueous solution, as
illustration is only a schematic representation and does not represent the actual
K.T. Al-Jamal et al. / Results in Pharma Sciences 2 (2012) 9–1512Heparin–dendrimer complexes, or dendriplexes, were sponta-
neously formed by mixing heparin and the cationic dendrimer in
aqueous solution, the formation presumably occurring via elec-
trostatic interactions, as illustrated in Fig. 1. The spherical
aggregates shown by TEM in Fig. 2A and B were not observed in
heparin or dendrimer solutions alone, indicating that theHydrodynamic size: 122± 1 nm. 
Zeta potential: -47 ± 2 mV 
Hydrodynamic size: 121± 2 nm. 
 Zeta potential: +52 ± 3 mV 
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Fig. 2. Transmission electron micrographs of dendriplexes showing quasi-sphe-
rical aggregates in the nano-size range at 1:1 dendrimer:heparin mass ratio
(A) and at 2:1 dendrimer:heparin mass ratio (B). (C) The mean Z-average diameter
(nm) of dendriplexes as a function of time (in days) at various dendrimer:heparin
mass ratios.
Table 1
Z-average diameter (nm) and zeta potential (mV) of dendriplexes formed on day 0,
from various dendrimer:heparin ratios.
Dendrimer:
heparin mass
ratio
Dendrimer:
heparin molar
ratioa
þ/
charge
ratiob
Z-average
diameter
(nm)7S.D.c
Zeta
potential
(mV)7S.D.c
0.5:1 1:1 1:1 99.074.0 38.071.6
1:1 2:1 2:1 122.071.0 47.072.0
2:1 4:1 4:1 121.072.0 þ52.073.0
3:1 6:1 6:1 147.073.0 þ55.074.0
4:1 8:1 8:1 147.071.5 þ56.072.0
5:1 10:1 10:1 136.072.0 þ60.072.0
a Based on the assumption that heparin has an 18,000 Da average molecular
weight.
b Based on the assumption that there are 69 negative charges per heparin
chain, and 64 positive charges per dendrimer. The þ/charge ratio was calculated
using the equations:
þ=Ratio¼ 2:05 Dendrimer½weight
Heparin½weight or 7Ratio¼ 0:92
Dendrimer½moles
Heparin½moles
c Mean7S.D. (n¼3).conﬁguration of the aggregates was speciﬁc to dendriplex forma-
tion. The mean intensity hydrodynamic diameter of the dendri-
plexes, prepared at varying dendrimer to heparin mass ratios, and
measured by PCS, ranged from 99.074.0 nm to 147.073.0 nm
(Table 1). Size was monitored and shown to be generally stable
for up to 14 days (Fig. 2C). However, the dendriplexes exhibited
a negative zeta potential (47 mV) at a 1:1 mass ratio (2:1þ/
charge or molar ratio), despite complete association (as will be
discussed in the MB/heparin assay). The zeta potential was0.8 
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Fig. 3. (A) UV/vis spectra of free methylene blue (MB) (lmax¼664 nm) and
MB–heparin (lmax¼568 nm). Upon dendrimer addition, the MB–heparin lmax
shifted to 664 nm indicating MB release from heparin due to dendrimer:heparin
complexation. (B) Titration of a MB (10 mM)–heparin (0.725 mM) mixture with the
dendrimer (0.16–10 mM). A maximum A664/A568 ratio was obtained at a 2:1þ/
charge ratio (1:1 or 2:1 dendrimer:heparin mass or molar ratio, respectively). This
is considered to be the ratio at which a maximum dendrimer:heparin association
occurred.
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Fig. 4. Heparin anticoagulant activity in vitro was measured using an antifactor Xa
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(0.8 IU/ml) began to decrease (and A405 increase) as the dendrimer:heparin mass
ratio increased from 0.5:1 to 3:1, with complete neutralization at a 1:1 ratio.
Symbols are the means of triplicate assays.
K.T. Al-Jamal et al. / Results in Pharma Sciences 2 (2012) 9–15 13positive (þ52 mV) at a 2:1 mass ratio (4:1þ/charge or molar
ratio) (Table 1).
The dendrimer/heparin charge ratio was calculated based on
the assumption of 18,000 Da average molecular weight for
heparin and 2.3 sulfate groups per disaccharide (Table 1). The
reason that the maximum association in dendrimer/heparin
systems occurred at 2:1þ/ , compared to 1:1þ/ in linear
polylysine/dendrimer systems [13] may be due to the non-
availability of all the amino groups of the dendrimers for0.0
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Fig. 5. (A) Heparin calibration was carried out using heparin spiked (0.0–1.6 IU/ml)
control pooled platelet-free rat plasma, and an antifactor Xa assay (n¼4; symbols
are means, 7S.D.). (B) Active heparin plasma concentration (IU/ml) in Sprague-
Dawley rats treated by subcutaneous injection with [3H]heparin (10 mg/Kg) (B), or
[3H]heparin dendriplex (10 mg/Kg heparin and 30 mg/Kg dendrimer) (&). Oral
[3H]heparin (100 mg/Kg) was used as a negative control ( ). There were 4 animals
in each treatment group at each time point (0 control, 1, 3, 6, and 24 h post-
administration).
Haematoma 
Fig. 6. (A) Subcutaneous injection site in the dorsal neck region at 1 h after the adminis
of [3H]heparin dendriplex (10/30 mg/Kg). In (A) there is evidence of hematoma formatio
the neck region has been deﬂected to the left and right of the mid line; the cranium isinteraction with sulfate groups. This could be related to steric
hindrance of the terminal amines with the hyperbranched den-
drimer structure, or to pH-dependent ionization of the dendrimer
amino groups. A further possibility is that the heparin used in the
present study was a polydisperse mixture of heparin chains,
whereas the assumption in calculating the þ/charge ratio was
based on a single molecular weight.3.2. Methylene blue/heparin assay
To conﬁrm that an electrostatic-type interaction was the
driving force for dendriplex formation, MB spectroscopy was
employed. MB is a cationic metachromatic dye with an afﬁnity
for polyanions such as heparin [10]. Unbound MB has a lmax of
664 nm whereas MB bound to heparin (MB–heparin) has a lmax of
568 nm (Fig. 3A). Dendrimer addition to MB–heparin caused a
shift in lmax from 568 to 664 nm. MB and MB–dendrimer exhibit
the same lmax of 664 nm, which excludes any interaction
between MB and the dendrimer. MB spectroscopy (A664/A568
ratio) was used to identify the ratio at which maximum
dendrimer–heparin association occurred. First, the optimum
heparin concentration required to produce a minimum A664/568
ratio was found experimentally, i.e. all MB molecules (10 mM)
were bound to heparin with no excess heparin (0.725 mM) in the
solution; excess free heparin in the medium would give an
inaccurate dendrimer/heparin association ratio. The MB–heparin
mixture was titrated with dendrimer (0.16–10 mM). A maximum
A664/A568 ratio was obtained at a 1:1 mass ratio (2:1þ/charge
ratio or molar ratio) (Fig. 3B). This result agrees with the zeta
potential measurement study, which showed a negative zeta
potential (47 mV) at this molar ratio, which then became
positive (þ52 mV) when the ratio was increased; this would
indicate the presence of excess dendrimer on the complex surface
at higher molar ratios.3.3. In vitro anticoagulant activity of heparin dendriplexes
Antithrombin III (AT-III) is a natural inhibitor of thrombin,
factor Xa and other coagulation proteases in plasma. The rate of
inhibition by AT-III is slow, but the rate can be increased several
thousand times by the presence of heparin. Thus the antifactor
Xa assay is a useful test to evaluate the anticoagulant activity of
heparin. A commercial antifactor Xa assay kit was used to
estimate the residual anticoagulant activity of heparin. Since both
factor Xa and AT-III are present in excess in the assay kit, the rate
of factor Xa inhibition is directly proportional to the heparin
concentration. The residual activity of factor Xa, as measured by
the absorbance of its chromogenic substrate at 405 nm, istration of [3H]heparin (10 mg/Kg). (B) Injection site at 1 h after the administration
n, while there is no evidence of hemorrhage in (B). In each image the dorsal skin in
towards the upper part of each image.
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Table 2
[3H]heparin and [3H]heparin dendriplex administration by subcutaneous injection
in the rat; percentage of administered dose per organ at 1, 3, 6 and 24 h after
treatmenta.
Organ 1 h 3 h 6 h 24 h
[3H]heparin
Plasma 1.7370.54 0.8370.19 0.5670.09 0.4570.04
Heart 0.1170.04 0.1270.09 0.0770.01 0.1070.04
Lung 0.1870.06 0.1570.03 0.1470.02 0.1270.01
Liver 1.1470.17 0.8770.05 0.8470.02 0.8670.18
Spleen 0.0470.01 0.0370.01 0.0770.06 0.0470.03
Kidney 1.8770.95 1.47v0.29 1.4970.69 1.1670.10
Stomach 0.1470.05 0.1870.07 0.2870.09 0.1270.05
Small intestine 0.8470.25 0.9070.38 0.5770.09 0.4370.06
Large intestine 0.3770.02 0.3670.07 0.4270.13 0.3470.06
[3H]heparin dendriplex
Plasma 1.2670.04 0.8270.15 0.6870.12 0.3570.06
Heart 0.0670.01 0.0670.00 0.0770.01 0.0570.01
Lung 0.0870.01 0.0970.00 0.0970.02 0.0670.01
Liver 0.9070.07 1.1370.13 1.5770.46 1.6270.36
Spleen 0.0570.02 0.0670.02 0.0670.01 0.0670.01
Kidney 0.8770.03 0.7070.07 0.7470.20 0.7270.12
Stomach 0.1370.06 0.0970.01 0.0770.02 0.0370.02
Small intestine 0.5970.56 0.3870.17 0.2270.02 0.1770.06
Large intestine 0.1270.01 0.1870.01 0.1870.02 0.1270.03
a Data are means, 7S.D. There were 4 animals in each treatment group at
each time point.
K.T. Al-Jamal et al. / Results in Pharma Sciences 2 (2012) 9–1514inversely proportional to the anticoagulant activity of heparin in
plasma.
The antifactor Xa assay was employed to study the effect of
complexation on the in vitro anticoagulant activity of heparin. The
USP unit is the measure of the anticoagulant activity of a given
heparin product using a USP reference standard based on units of
heparin activity per mg, and the heparin used in the present work
has 180 USP units/mg. It was found that when dendrimer was
bound, neutralisation of anticoagulant activity occurred (Fig. 4);
heparin spiked (0.8 IU/ml) in human plasma was inactive at a 1:1
heparin:dendrimer mass ratio. This further conﬁrmed the result
obtained by MB spectroscopy which showed that the maximum
association between heparin and dendrimer also occurred at the
1:1 mass ratio. The new conformation of heparin is considered to
abolish the negative charge and make it inaccessible to AT-III and
the coagulation proteases (i.e. prothrombin III and factor Xa), a
process, which inactivates anticoagulant activity.3.4. In vivo anticoagulant activity of heparin and heparin
dendriplexes after subcutaneous administration in the rat
Heparin dendriplexes demonstrated no anticoagulant activity
in vitro, however it was considered of interest to determine if the
behavior of such macromolecular complexes could allow activity
in complex biological systems; events such as partitioning1 h
3 h
6 h
24 h
Large
intestine
1 h
3 h
6 h
24 h
Kidneys Stomach Small
intestine
pleen
Large
intestine
Kidneys Stomach Small
intestine
pleen
]heparin dendriplex (B), after subcutaneous injection in the rat, at 1, 3, 6 and 24 h
K.T. Al-Jamal et al. / Results in Pharma Sciences 2 (2012) 9–15 15between the dendrimer and heparin binding peptides may occur,
as the binding of heparin to heparin binding peptides has been
reported in plasma following intravenous administration [14].
Other effects that could occur in vivo include an interaction with
extracellular matrices after subcutaneous injection and/or inter-
actions with intracellular components following cellular uptake
(e.g. susceptibility to endosomal escape following endocytosis).
To investigate whether heparin was able to regain antic-
oagulant activity in vivo, rats were injected subcutaneously with
free or complexed heparin. Heparin anticoagulant activity in
platelet-free rat plasma was estimated at 0, 1, 3, 6 and 24 h
post-injection using the antifactor Xa assay. The heparin calibra-
tion curve in platelet-free pooled rat plasma was plotted (Fig. 5A)
and the active heparin concentration in the plasma determined
(Fig. 5B). It can be seen (Fig. 5B) that heparin injected subcuta-
neously at a dose of 10 mg/Kg was therapeutically active up to 6 h
post-administration and complete loss of its activity was
observed at 24 h time point. However, heparin dendriplexes at a
1:3 heparin:dendrimer mass ratio (10/30 mg/Kg) (a ratio above
maximum association), resulted in an inactive complex in vivo;
this lack of activity compared with the oral heparin-treated
groups. At autopsy, gross observations were made on the injec-
tion site in animals treated with heparin and heparin dendri-
plexes. In animals injected with heparin there was evidence of
subcutaneous hematoma formation (i.e. localized extravasated
blood). There was no evidence of hemorrhage at the injection site
in animals treated with heparin dendriplex (Fig. 6).
It was considered that the lack of anticoagulant activity in vivo
in rats treated with heparin dendriplexes may have been due to
the precipitation of the aggregates at the site of subcutaneous
injection. Therefore, an estimation of the total heparin concentra-
tion (both active and inactive) was carried out by measuring the
radioactivity of free heparin and heparin dendriplexes in the
plasma and major organs, at a series of time points after
subcutaneous administration. Data obtained from radioactivity
measurements (Table 2) demonstrated that the administration of
both free and complexed heparin lead to the identiﬁcation of
radioactivity in the plasma and the major organs. This ﬁnding
implied that heparin dendriplex inactivity could be attributed to
complexation and not to precipitation at the site of administra-
tion. Results from biodistribution studies (Fig. 7) show that both
heparin and heparin dendriplexes have the highest levels in the
kidney, with reductions in plasma and kidney levels as a function
of time.
The reported results conﬁrm that the polycationic hyper-
branched poly-L-lysine dendrimer has great afﬁnity to the poly-
anionic heparin which could be of interest in developing further
and in more predictable manner new heparin-binding anti-
angiogenic therapeutics. Furthermore, it further indicates heparinbinding to poly-L-Lysine dendrimer could be one of the postu-
lated mechanisms behind the dendrimer intrinsic anti-angiogenic
activity.Acknowledgments
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